{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=7",
    "query": {
      "condition": "Phase I",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 18735,
    "total_pages": 1874,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-06T01:04:21.057Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00958074",
      "title": "Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cutaneous T-cell Lymphoma Stage I",
        "Cutaneous T-cell Lymphoma Stage II",
        "Cutaneous T-cell Lymphoma Stage III",
        "Cutaneous T-cell Lymphoma Stage IV"
      ],
      "interventions": [
        {
          "name": "vorinostat",
          "type": "DRUG"
        },
        {
          "name": "flow cytometry",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2009-07",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2018-10-18",
      "last_synced_at": "2026-11-06T01:04:21.057Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00958074"
    },
    {
      "nct_id": "NCT07008118",
      "title": "A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "INCA035784",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2025-10-01",
      "completion_date": "2029-12-14",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-11-06T01:04:21.057Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Palo Alto, California • Denver, Colorado + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07008118"
    },
    {
      "nct_id": "NCT04839991",
      "title": "Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced and/or Metastatic Solid Tumours"
      ],
      "interventions": [
        {
          "name": "CB307",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Crescendo Biologics Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2021-06-08",
      "completion_date": "2024-09-25",
      "has_results": false,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-11-06T01:04:21.057Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04839991"
    },
    {
      "nct_id": "NCT00666991",
      "title": "Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Peritoneal Neoplasms"
      ],
      "interventions": [
        {
          "name": "nanoparticulate paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CritiTech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2008-07",
      "completion_date": "2013-05",
      "has_results": false,
      "last_update_posted_date": "2014-02-27",
      "last_synced_at": "2026-11-06T01:04:21.057Z",
      "location_count": 3,
      "location_summary": "Kansas City, Kansas • Wichita, Kansas • Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00666991"
    },
    {
      "nct_id": "NCT04438174",
      "title": "Processed Amniotic Fluid (pAF) for the Treatment of Chronic Wounds",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Wounds and Injuries"
      ],
      "interventions": [
        {
          "name": "Processed Amniotic Fluid",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care Wound Treatment Regimen",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 1,
      "start_date": "2022-08",
      "completion_date": "2023-03",
      "has_results": true,
      "last_update_posted_date": "2024-06-07",
      "last_synced_at": "2026-11-06T01:04:21.057Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04438174"
    },
    {
      "nct_id": "NCT01656018",
      "title": "A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "TMC278, Long acting (LA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 4,
      "start_date": "2012-11",
      "completion_date": "2016-01",
      "has_results": false,
      "last_update_posted_date": "2016-04-07",
      "last_synced_at": "2026-11-06T01:04:21.057Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01656018"
    },
    {
      "nct_id": "NCT06072040",
      "title": "Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Microtia"
      ],
      "interventions": [
        {
          "name": "AUR-201",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Auregen Biotherapeutics, SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "8 Years to 29 Years"
      },
      "enrollment_count": 3,
      "start_date": "2024-01-26",
      "completion_date": "2025-11-14",
      "has_results": false,
      "last_update_posted_date": "2025-11-21",
      "last_synced_at": "2026-11-06T01:04:21.057Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06072040"
    },
    {
      "nct_id": "NCT01505868",
      "title": "Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Castration Levels of Testosterone",
        "Castration-Resistant Prostate Carcinoma",
        "Lymphadenopathy",
        "Metastatic Prostate Carcinoma",
        "Prostate Adenocarcinoma",
        "Prostate Carcinoma Metastatic in the Bone",
        "Prostate Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cabazitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 170,
      "start_date": "2012-07-11",
      "completion_date": "2019-12-09",
      "has_results": true,
      "last_update_posted_date": "2021-07-30",
      "last_synced_at": "2026-11-06T01:04:21.057Z",
      "location_count": 2,
      "location_summary": "Detroit, Michigan • Houston, Texas",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01505868"
    },
    {
      "nct_id": "NCT02873650",
      "title": "Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "dabrafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 5,
      "start_date": "2016-12-20",
      "completion_date": "2019-04-08",
      "has_results": false,
      "last_update_posted_date": "2020-12-08",
      "last_synced_at": "2026-11-06T01:04:21.057Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • DeBary, Florida • Berlin, New Jersey + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "DeBary",
          "state": "Florida"
        },
        {
          "city": "Berlin",
          "state": "New Jersey"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02873650"
    },
    {
      "nct_id": "NCT01833520",
      "title": "Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "Ra-223 Dichloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2013-10-16",
      "completion_date": "2020-04-08",
      "has_results": true,
      "last_update_posted_date": "2021-02-02",
      "last_synced_at": "2026-11-06T01:04:21.057Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01833520"
    }
  ]
}